%0期刊文章%@ 2369- 2960% I JMIR出版物%V 6%卡塔尔世界杯8强波胆分析 N 4% P e22521% T与典型COVID-19症状几率较低的药物的关联:横断面症状监测研究%A Urbach,Dietmar %A Awiszus,Friedemann %A lee ß，Sven %A Venton,Tamsin %A Specht,Alexander Vincent De %A Apfelbacher, Otto von Guericke大学Christian %+骨科，莱比锡街44号，39122，马格德堡，39122，德国，49 537187 ext 3353，dietmar.urbach@med.ovgu.de %K COVID-19 %K SARS-CoV-2 %K他汀类药物%K抗高血压药物%K监测%K羟甲基戊二酰辅酶A还原酶抑制剂%K在线调查%D 2020 %7 14.12.2020 %9原始论文%J JMIR公共卫生监测%G英文%X背景:随着COVID-19大流行继续在全球蔓延，寻找治疗COVID-19症状的有效药物的工作也在继续。最好确定一种已经用于治疗另一种疾病的药物，其副作用和安全性数据已经已知并得到批准。目的:本研究的目的是通过使用在线监测调查的数据，评估不同药物对典型COVID-19症状的影响。方法:在2020年4月初至7月底期间，德国下萨克森州共有3654人通过应用程序covid-nein-danke.de参加了一项在线症状跟踪调查。问卷内容包括COVID-19典型症状、年龄范围、性别、在面向患者的医疗机构就业、住房状况、邮政编码、既往病史、长期用药、疫苗接种状况、逆转录聚合酶链反应(RT-PCR)结果和COVID-19诊断抗体检测结果，以及后续COVID-19治疗(如适用)。使用逻辑回归模型计算每种药物和症状对应95% ci的优势比估计值。结果:数据分析表明，参与者自我报告的典型COVID-19症状与自我报告的他汀类药物治疗以及在较小程度上的抗高血压治疗之间存在统计学上显著的负相关关系。当COVID-19诊断基于限制性症状标准(即存在7种症状中的4种)或RT-PCR检测阳性时，仅发现他汀类药物具有统计学意义的相关性(优势比0.28,95% CI 0.1-0.78)。 Conclusions: Individuals taking statin medication are more likely to have asymptomatic COVID-19, in which case they may be at an increased risk of transmitting the disease unknowingly. We suggest that the results of this study be incorporated into symptoms-based surveillance and decision-making protocols in regard to COVID-19 management. Whether statin therapy has a beneficial effect in combating COVID-19 cannot be deduced based on our findings and should be investigated by further study. Trial Registration: German Clinical Trials Register DRKS00022185; https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022185; World Health Organization International Clinical Trials Registry Platform U1111-1252-6946 %M 33197879 %R 10.2196/22521 %U http://publichealth.www.mybigtv.com/2020/4/e22521/ %U https://doi.org/10.2196/22521 %U http://www.ncbi.nlm.nih.gov/pubmed/33197879